11 Billion for this pipeline would make MSB's estimated valuation rather large by comparison.
Prometheus Biosciences therapeutic pipeline
Program Indication Preclinical Phase 1 Phase 2 Phase 3 PRA023
TL1A mAbUlcerative Colitis Crohn's Disease SSc-ILD PRA052*
CD30 ligand mAbImmune-Mediated Diseases PR1100
Cytokine receptor mAbImmune-Mediated Diseases PR2100
Inflammatory cytokine mAbImmune-Mediated Diseases PR300
GPCR small moleculeImmune-Mediated Diseases *Partnered with Dr. Falk Pharma in Europe, Australia, and New Zealand
Cell Therapy News/Articles, page-16089
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
0.045(3.33%) |
Mkt cap ! $1.592B | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.42 | $1.33 | $3.802M | 2.753M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 23940 | $1.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 22571 | 2 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |